H.C. Wainwright lowered the firm’s price target on Alumis (ALMS) to $15 from $19 and keeps a Buy rating on the shares following the Q4 report. The firm cites the impact of increased projected operating expenses on the stock’s valuation for the target cut.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ALMS:
- Promising Efficacy of Alumis Inc.’s ESK-001 in Psoriasis Treatment Boosts Market Position and Buy Rating
- Alumis announces data from the OLE of its Phase 2 STRIDE trial
- Promising Developments in Alumis Inc.’s Clinical Programs Support Buy Rating
- Alumis Inc. Announces Merger with ACELYRIN, Inc.
- Acelyrin says Concentra indication not expected to result in superior proposal